ReviewFrontiers in immunology2023
The impact of the COVID-19 pandemic on the global tuberculosis epidemic.
Review in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 79 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
79 citing papers in PubMed, 2 syntheses or guidelines pooled it, 104 citations in OpenAlex.
- Pooled it
- Quantifying the evidence and burden of smoking behaviour on tuberculosis incidence among adult population: a systematic review and meta-analysis.Journal of global health · 2026Pooled it
- Changes in the incidence and profile of pediatric tuberculosis in France from 2014 to 2023: impact of COVID-19 non-pharmaceutical interventions implementation and lifting.European journal of pediatrics · 2026Article
- Article
- Mycobacterium tuberculosis and SARS-CoV-2 Co-Infection: An Efficient Cell Model to Study Lung Host-Pathogen Interactions.Current protocols · 2026Article
- Induced alanine auxotrophy as a therapeutic strategy against Mycobacterium tuberculosis.Research square · 2026Article
- Spatiotemporal trends in tuberculosis incidence in Thailand, 2012-2023: a nationwide, province-level analysis.Infectious diseases of poverty · 2026Article
- Prevalence and determinants of tuberculosis and COVID-19 among patients with presumptive tuberculosis in a Nigerian tertiary hospital.BMC infectious diseases · 2026Article
- Induced alanine auxotrophy as a therapeutic strategy againstbioRxiv : the preprint server for biology · 2026Article
- A Narrative Review of the Regional Prospective Observational Research in Tuberculosis International Consortium: Sharing Diverse Data and Specimens in the Fight Against Tuberculosis.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Review
- Modelling the impact of increasing tuberculosis treatment coverage and addressing determinants of risk in men.Communications medicine · 2026Article
- Global, Regional, and National Burden of Tuberculosis Among Children: A Population-Based Study.Tropical medicine and infectious disease · 2026Article
- Transmission heterogeneity amongiScience · 2026Article
- The Americas are not on track to end TB: tuberculosis incidence analysis under the 2025 WHO goals.Frontiers in public health · 2026Article
- Reimagining tuberculosis elimination in India: diagnostics, drug resistance, and digital health strategies.Frontiers in epidemiology · 2026Review
- Profiling complement proteins in pediatric tuberculosis children with or without serological evidence of prior SARS-CoV-2 exposure.Frontiers in immunology · 2026Article
- In silico framework for designing and validating a multi-stage subunit vaccine against Tuberculosis using reverse vaccinology approach.PloS one · 2026Article
- Public Search Behavior and Tuberculosis Cases in Indonesia 2019-2023: An Infodemiology Study Using Google Trends .F1000Research · 2026Article
- Article
- Disseminated Tuberculosis Masquerading as Malignancy in an Immunocompetent Middle-aged Woman: A Multiorgan Imaging Case Report and Updated Review for CliniciansCurrent medical imaging · 2026Review
19 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
Tuberculosis (TB) is a major cause of ill health worldwide. Until the coronavirus (COVID-19) pandemic, TB was the leading cause of death from a single infectious agent. COVID-19 has caused enormous health, social and economic upheavals since 2020, impairing access to essential TB services. In marked contrast to the steady global increase in TB detection between 2017 and 2019, TB notifications dropped substantially in 2020 compared with 2019 (-18%), with only a partial recovery in 2021. TB epidemiology worsened during the pandemic: the estimated 10.6 million people who fell ill with TB worldwide in 2021 is an increase of 4.5% from the previous year, reversing many years of slow decline. The annual number of TB deaths worldwide fell steadily between 2005 and 2019, reaching 1.4 million in 2019, but this trend was reversed in 2020 (1.5 million), and by 2021 global TB deaths were back to the level of 2017 (1.6 million). Intensified efforts backed by increased funding are urgently required to reverse the negative impacts of COVID-19 on TB worldwide, made more pressing by ongoing conflicts, a global energy crisis and uncertainties in food security that are likely to worsen the broader determinants of TB.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.